Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Optimization of Ceftazidime Regimen in Critical Care
NCT07085624Not yet recruiting
- Sponsor
- CHU Saint-Etienne
- Start
- Oct 2026
- Primary completion
- Nov 2026
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Randomised trial of ceftazidime in sepsis, septic shock and Pseudomonas aeruginosa infection (2 arms), sponsored by CHU Saint-Etienne. Primary endpoint: Percentage of subjects with ceftazidime concentration within target range at 24 hours. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ceftazidime
03
Conditions
sepsisseptic shockPseudomonas aeruginosa infection
Beyond the preview
Go deeper on NCT07085624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07085624.